We have located links that may give you full text access.
Journal Article
Review
Metformin in pregnancy and childhood neurodevelopmental outcomes: a systematic review and meta-analysis.
American Journal of Obstetrics and Gynecology 2024 March 8
OBJECTIVE: To examine the impact of maternal metformin use in pregnancy on offspring neurodevelopmental outcomes.
DATA SOURCES: MEDLINE, Embase, and Web of Science (Core Collection) were searched from inception until July 1, 2023.
STUDY ELIGIBILITY CRITERIA: Studies of women receiving treatment with metformin at any stage of pregnancy for any indication, with neurodevelopmental data available for their offspring were included. Studies without a control group were excluded. Randomised controlled trials, case-control, cohort and cross-sectional studies were included in the review.
STUDY APPRAISAL AND SYNTHESIS METHODS: Studies were screened for inclusion, and data extracted independently by two reviewers. Risk of bias was assessed using a modified version of the Newcastle-Ottawa Scale for non-randomised studies, and the Risk of Bias 2 tool for randomised trials.
RESULTS: Seven studies met inclusion criteria, including a combined 14,042 children, with 7,641 exposed children up to 14 years of age. Metformin use in pregnancy was not associated with neurodevelopmental delay in infancy (relative risk [RR] 1.09 (95% confidence interval (CI) 0.54-2.17; 3 studies; 9,668 children) or at ages 3-5 (RR 0.90 (95%CI 0.56-1.45); 2 studies; 6,118 children). When compared with unexposed peers, metformin use in pregnancy was not associated with altered motor scores (mean difference 0.30 (95%CI -1.15-1.74); 3 studies; 714 children), or cognitive scores (mean difference -0.45 (95%CI -1.45-0.56); 4 studies; 734 children). Studies included were of high quality and deemed to be of low risk of bias.
CONCLUSIONS: In-utero exposure to metformin does not seem to be associated with adverse neurodevelopmental outcomes in children up to the age of 14. These findings provide reassurance to clinicians and pregnant women considering metformin use during pregnancy.
DATA SOURCES: MEDLINE, Embase, and Web of Science (Core Collection) were searched from inception until July 1, 2023.
STUDY ELIGIBILITY CRITERIA: Studies of women receiving treatment with metformin at any stage of pregnancy for any indication, with neurodevelopmental data available for their offspring were included. Studies without a control group were excluded. Randomised controlled trials, case-control, cohort and cross-sectional studies were included in the review.
STUDY APPRAISAL AND SYNTHESIS METHODS: Studies were screened for inclusion, and data extracted independently by two reviewers. Risk of bias was assessed using a modified version of the Newcastle-Ottawa Scale for non-randomised studies, and the Risk of Bias 2 tool for randomised trials.
RESULTS: Seven studies met inclusion criteria, including a combined 14,042 children, with 7,641 exposed children up to 14 years of age. Metformin use in pregnancy was not associated with neurodevelopmental delay in infancy (relative risk [RR] 1.09 (95% confidence interval (CI) 0.54-2.17; 3 studies; 9,668 children) or at ages 3-5 (RR 0.90 (95%CI 0.56-1.45); 2 studies; 6,118 children). When compared with unexposed peers, metformin use in pregnancy was not associated with altered motor scores (mean difference 0.30 (95%CI -1.15-1.74); 3 studies; 714 children), or cognitive scores (mean difference -0.45 (95%CI -1.45-0.56); 4 studies; 734 children). Studies included were of high quality and deemed to be of low risk of bias.
CONCLUSIONS: In-utero exposure to metformin does not seem to be associated with adverse neurodevelopmental outcomes in children up to the age of 14. These findings provide reassurance to clinicians and pregnant women considering metformin use during pregnancy.
Full text links
Related Resources
Trending Papers
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Prevention and treatment of ischaemic and haemorrhagic stroke in people with diabetes mellitus: a focus on glucose control and comorbidities.Diabetologia 2024 April 17
British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease.Rheumatology 2024 April 17
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Albumin: a comprehensive review and practical guideline for clinical use.European Journal of Clinical Pharmacology 2024 April 13
Eosinophilic Esophagitis: Clinical Pearls for Primary Care Providers and Gastroenterologists.Mayo Clinic Proceedings 2024 April
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app